AGTC News and Press, Applied Genetic Technologies Corporation From 01/11/22

Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022 Company providing further updated guidance on other milestones GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 20...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment o...

In the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below. For f...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatm...

With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal d...

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022 Initiating clinical safety evaluation of higher dos...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseas...

Applied Genetic Technologies Corporation (AGTC) Q1 Fiscal Year Earnings Conference Call November 9, 2021, 8:00 AM ET Company Participants Sue Washer – CEO Jon Lieber – Chief Financial Officer Susan Schneider – Chief Medical Officer Conference Call Participants Joe Pantgin...

Applied Genetic (NASDAQ:AGTC): FQ1 GAAP EPS of -$0.40 misses by $0.05. Press Release As of September 30, 2021, the Company's cash and cash equivalents totaled $90.5 million.  Management believes that these funds will be sufficient to allow the Company to generate data from its ...